Benchmark downgraded Staar Surgical to Hold from Buy and removed the firm’s price target after the company laid out its plan to reignite sales growth between 2024 and 2026 yesterday at an investor event. The lingering question coming into the meeting was whether the U.S. sales effort could ramp quickly enough in the next two years to reaccelerate growth as the Chinese market matures, though the plan “was not dramatically different than what was sketched out” during the Q2 call, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on STAA:
- Staar Surgical sees FY26 sales $500M-$550M, operating margin of 12%-16%
- Staar Surgical to replace Urstadt Biddle in S&P 600 at open on 8/22
- Dolby to replace Staar Surgical in S&P 400 at open on 8/22
- Staar Surgical price target lowered to $45 from $50 at Stifel
- Staar Surgical price target lowered to $57 from $71 at Stephens